Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $577.1 million.

  • Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity fell 2523.15% to $577.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 340.86%. This contributed to the annual value of $742.4 million for FY2024, which is 5137.98% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Liabilities and Shareholders Equity stood at $577.1 million for Q3 2025, which was down 2523.15% from $582.3 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity registered a high of $771.9 million during Q3 2024, and its lowest value of $118.2 million during Q2 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Liabilities and Shareholders Equity value was $435.1 million (recorded in 2022), while the average stood at $421.2 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity surged by 57372.77% in 2021 and then tumbled by 2538.09% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity (Quarter) stood at $203.7 million in 2021, then surged by 113.58% to $435.1 million in 2022, then increased by 12.72% to $490.4 million in 2023, then surged by 51.38% to $742.4 million in 2024, then dropped by 22.26% to $577.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $577.1 million in Q3 2025, compared to $582.3 million in Q2 2025 and $661.0 million in Q1 2025.